Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results ; volume:31 ; number:03 ; year:2010 ; pages:76-78
Indian journal of medical & paediatric oncology ; 31, Heft 03 (2010), 76-78
- Contributor
-
Goel, Arun Kumar
Nandy, Malay
Sharma, Gopal
- DOI
-
10.4103/0971-5851.73588
- URN
-
urn:nbn:de:101:1-2022031216420417398911
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Goel, Arun Kumar
- Nandy, Malay
- Sharma, Gopal
Other Objects (12)
Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
Exciting
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer
Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Does T1c–2N0–1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
Exciting
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer
Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Does T1c–2N0–1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
Exciting
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer
Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?